Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical patterns in social cognition & personality changes in progressive supranuclear palsy.

Journal of neurology·2026

Same author

Imaging the later-life white matter pathologies of repetitive head impacts: A novel pattern revealed through T2 FLAIR MRI.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

Additive effect of patient anosognosia and theory of mind deficit on dementia caregiver distress.

Frontiers in neurology·2026

Same author

Network-based cortical atrophy predicts longitudinal clinical decline in sporadic behavioral variant frontotemporal dementia.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

Same author

Design considerations for C9orf72 disease prevention trials.

Brain : a journal of neurology·2025

Same author

Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.

Nature neuroscience·2025

Search research articles

Related Experiment Videos

Dextromethorphan/quinidine sulfate for pseudobulbar affect.

¹UCSF Department of Neurology, Memory and Aging Center, San Francisco, California 94143, USA. hrosen@memory.ucsf.edu

Drugs of Today (Barcelona, Spain : 1998)

|January 13, 2009

Summary

A new dextromethorphan (DM) and quinidine (Q) combination agent shows promise for treating pseudobulbar affect (PBA). This agent demonstrated safety and efficacy in large studies, potentially offering the first FDA-approved treatment for PBA.

Related Experiment Videos

Area of Science:

Neuroscience
Pharmacology
Neurology

Background:

Pseudobulbar affect (PBA) is a neurological disorder characterized by uncontrollable emotional outbursts.
Current treatments for PBA, such as antidepressants, have limitations in efficacy and data quality.
The pathophysiology of PBA is not fully understood but is linked to neurological diseases and potential brain stem dysregulation.

Purpose of the Study:

To evaluate the efficacy and safety of a new combination agent, dextromethorphan (DM) and quinidine (Q), for the treatment of PBA.
To explore the potential of DM/Q as the first FDA-approved medication for PBA.

Main Methods:

Two large-scale studies were conducted involving patients with PBA, primarily those with amyotrophic lateral sclerosis (ALS) and multiple sclerosis.
The studies assessed the safety and tolerability of the DM/Q combination agent.
Efficacy was measured by the reduction in the severity of PBA symptoms.

Main Results:

The DM/Q combination agent was found to be effective in reducing the severity of PBA symptoms in patients with ALS and multiple sclerosis.
The agent was demonstrated to be safe and relatively well tolerated.
These represent the largest treatment studies for PBA conducted to date.

Conclusions:

The DM/Q combination agent shows significant potential as a novel treatment for PBA.
Further research is ongoing to optimize dosage, particularly the quinidine component.
If approved, DM/Q would be the first dedicated pharmaceutical treatment for PBA.